Aspen’s 1-year data for Parkinson’s cell therapy plant seeds for phase 3 trial

Aspen Neuroscience’s stem cell therapy improved Parkinson’s disease symptoms for all eight treated patients after one year, with the San Diego biotech now planning for a pivotal phase 3 trial later this year.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks